MediciNova Revenue and Competitors
Estimated Revenue & Valuation
- MediciNova's estimated annual revenue is currently $2.8M per year.
- MediciNova's estimated revenue per employee is $155,000
Employee Data
- MediciNova has 18 Employees.
- MediciNova grew their employee count by 13% last year.
MediciNova's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO, and Founder | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
MediciNova Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is MediciNova?
N/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MediciNova News
2022-04-17 - MediciNova Announces Publication of MN-166 (ibudilast ...
LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the...
2022-04-17 - MediciNova Announces Publication of MN-166 (ibudilast ...
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research.
2022-04-13 - MediciNova Announces Completion of Enrollment in the ...
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 18 | -40% | N/A |
#2 | $2.4M | 18 | -33% | N/A |
#3 | $1.4M | 18 | -18% | N/A |
#4 | $1.4M | 18 | -10% | $406.5M |
#5 | $1.4M | 18 | -33% | $173M |